When was Resverlogix founded?

Resverlogix was founded in 2001 and raised its 1st funding round 9 years after it was founded.

Where is Resverlogix located?

Resverlogix is headquartered in Calgary, Canada.

How many employees does Resverlogix have?

As of Mar 01, 2026, the latest employee count at Resverlogix is 10 - 49.

Is Resverlogix a funded company?

Resverlogix is a funded company, having raised a total of $129M across 19 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Jan 2010.

When was the latest funding round of Resverlogix?

Resverlogix's latest funding was a $***** Post IPO round on Oct 06, 2020, with participation from 0 investor.

Where does Resverlogix rank among its competitors?

Resverlogix ranks 248th amongst 984 active competitors, of which 307 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Resverlogix?

Resverlogix's top competitors include BridgeBio, Alnylam and PTC Therapeutics. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Resverlogix - 2026 Company Profile, Team, Funding & Competitors

Resverlogix is a public company based in Calgary (Canada), founded in 2001 by Norman Wong and Don McCaffrey. It operates as a Provider of small molecule BET-inhibitors for CV disease for treating diabetes. Resverlogix has raised $129M in funding. The company has 984 active competitors, including 307 funded and 273 that have exited. Its top competitors include companies like BridgeBio, Alnylam and PTC Therapeutics.

Company Details

Resverlogix is a provider of small molecule BET-inhibitors for CV disease for treating diabetes. It is a late clinical-stage biopharma developing selective BET-inhibitors for CV disease in Diabetes patients. The company's lead candidate is Apabetalone (RVX-208), a first-in-class, small-molecule selective BET bromodomain inhibitor (selective to BRD4-BD2). The company has a proprietary epigenetics drug development platform and has identified additional compounds based on targeting BET (Bromodomain and extra-terminal Domain) proteins.

Website: www.resverlogix.com/
Social
Email ID: *****@resverlogix.com

Key Metrics

Founded Year

2001

Location

Calgary, Canada

Stage

Public

Total Funding

$129M in 19 rounds

Latest Funding Round

Post IPO, Oct 06, 2020, $*****

Investors

Shenzhen Hepalink Pharmaceutical & 4 more

Ranked

248^th among 984 active competitors

Employee Count

10 - 49 as on Mar 01, 2026

Similar Companies

BridgeBio & 1078 more

Exit Details

Public

View Resverlogix's full profile

Resverlogix got listed on Jan 17, 2005.

Click here to take a look at Resverlogix's IPO in detail

Resverlogix has raised a total funding of $129M over 19 rounds. Its first funding round was on Jan 2010. Resverlogix has 5 institutional investors.

Here is the list of recent funding rounds of Resverlogix:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 06, 2020	6398050	Post IPO	6660898	3504339	3025632	5659638
Aug 14, 2020	2852188	Post IPO	3320188	7086254	6241699	Shenzhen Hepalink Pharmaceutical
Sep 27, 2019	8968064	Conventional Debt	9915361	8323684	1628219	3371054

Access funding benchmarks and valuations. Sign up today!

View details of Resverlogix's funding rounds and investors

The founders of Resverlogix are Norman Wong and Don McCaffrey.

Here are the details of Resverlogix's key team members:

Norman Wong: Co-Founder & Chief Scientific Officer of Resverlogix. They are also an angel investor in 1 startup.
Don McCaffrey: President, Co-Founder & CEO of Resverlogix.

View details of Resverlogix's Founder profiles and Board Members

Resverlogix's employee count trend

Resverlogix has 10 - 49 employees as of Mar 26. Here is Resverlogix's employee count trend over the years:

Uncover Resverlogix's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Resverlogix include BridgeBio, Alnylam and PTC Therapeutics. Here is the list of Top 10 competitors of Resverlogix, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BridgeBio 2015, Palo Alto (United States), Public	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 20 others	81/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
5th	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	74/100
6th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
7th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
8th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	71/100
9th	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	TVM Capital, Forbion & 10 others	71/100
10th	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Flagship Pioneering ... & 6 others	70/100
248th	Resverlogix 2001, Calgary (Canada), Public	Provider of small molecule BET-inhibitors for CV disease for treating diabetes	$129M	Shenzhen Hepalink Pharmaceutical, NGN Capital ... & 3 others	45/100